Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age

NCT05349617 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT05349617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05349617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Completed
Start date
May 12, 2022
Completion date
August 8, 2023
Enrollment
413 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus